The Oncotype DX assay is recommended in international guidelines to guide adjuvant chemotherapy treatment decisions for women with early-stage, oestrogen receptor (ER)-positive, HER2-negative breast cancer [11–14]. Here, ERBB2 is linked to breast cancer.